



**GUIDELINE**

**Sepsis and Bacteraemia: Paediatric**

<b>Scope (Staff):</b>	Medical, Nursing, Pharmacy
<b>Scope (Area):</b>	Perth Children's Hospital (PCH)

**Child Safe Organisation Statement of Commitment**

CAHS commits to being a child safe organisation by applying the National Principles for Child Safe Organisations. This is a commitment to a strong culture supported by robust policies and procedures to reduce the likelihood of harm to children and young people.

This document should be read in conjunction with this [disclaimer](#)

- In patients with suspected sepsis, microbiological cultures must be collected and antimicrobial therapy should be given as soon as possible, ideally within 15 minutes of sepsis recognition. If collection of specimens for culture (e.g. lumbar puncture) is delayed, DO NOT DELAY ANTIBIOTIC ADMINISTRATION.
- Read this guideline in conjunction with the [Emergency Department Guidelines: Sepsis Recognition and Management](#)
- Empiric antibiotics are listed below in the order they should be administered. The administration of ceftriaxone, cefotaxime, cefepime or gentamicin should be prioritised above vancomycin which has a longer infusion time.
- Empirical regimens are intended for initial therapy (up to 48 hours only) therapy should be modified as soon as additional information is available.
- **Refer to the separate ChAMP guidelines for children with [Presumed Meningitis and Meningoencephalitis](#) or [Fever and Suspected or Confirmed Neutropenia: Empiric Guidelines](#)**

Compassion

Excellence

Collaboration

Accountability

Equity

Respect

CLINICAL SCENARIO		DRUGS/DOSES		
		Standard Protocol	Known or Suspected MRSA <sup>a</sup>	Low risk Penicillin allergy <sup>b</sup>
<p>Neonatal viral infections can sometimes present with neonatal sepsis. Consider herpes simplex virus (HSV) testing and <b>ADD</b> IV aciclovir for suspected HSV infection; dose as per <a href="#">KEMH neonatal guidelines</a>. For further information refer to <a href="#">ASID perinatal guidelines</a></p> <p>HSV infection may manifest as:</p> <ul style="list-style-type: none"> <li>• Localised skin, eye and mucous membranes disease (~45%)</li> <li>• Central nervous system (CNS) disease (~30%)</li> <li>• Disseminated disease - liver, lungs +/- CNS) (~25%)</li> </ul> <p>Maternal history of HSV may be absent in &gt;75% cases of neonatal HSV and up to 40% of neonatal HSV cases will not have skin lesions. Disseminated disease presents with viral sepsis, and may be indistinguishable from sepsis of another cause, i.e. respiratory collapse, pneumonitis, liver failure, disseminated intravascular coagulation (DIC). CNS disease presents with lethargy, poor feeding, bulging fontanel and seizures.</p>				
Neonatal sepsis (<4 weeks old Corrected Gestational Age)	Early onset <u>neonatal</u> sepsis (within 72 hours of birth) Meningitis excluded	IV gentamicin <b>AND</b> IV benzylpenicillin doses as per <a href="#">neonatal guidelines</a>	As per standard protocol	Discuss with ID or Microbiology service
		Neonatal viral infections <sup>c</sup> can sometimes present with neonatal sepsis. Consider HSV testing and <b>ADD</b> IV aciclovir for suspected HSV infection; dose as per <a href="#">KEMH neonatal guidelines</a> . For further information refer to <a href="#">ASID perinatal guidelines</a>		
	Early onset <u>neonatal</u> sepsis (within 72 hours of birth) Meningitis NOT excluded	IV cefotaxime <b>AND</b> IV benzylpenicillin doses as per <a href="#">neonatal guidelines</a>	As per standard protocol	Discuss with ID or Microbiology service
		Neonatal viral infections <sup>c</sup> can sometimes present with neonatal sepsis. Consider HSV testing and <b>ADD</b> IV aciclovir for suspected HSV infection; dose as per <a href="#">KEMH neonatal guidelines</a> . For further information refer to <a href="#">ASID perinatal guidelines</a>		

CLINICAL SCENARIO		DRUGS/DOSES			
		Standard Protocol	Known or Suspected MRSA <sup>a</sup>	Low risk Penicillin allergy <sup>b</sup>	High risk Penicillin allergy <sup>b</sup>
Neonatal sepsis (<4 weeks old Corrected Gestational Age)	Late onset (hospital acquired) <u>neonatal</u> sepsis (≥72 hours old)	IV gentamicin <b>AND</b> IV vancomycin doses as per <a href="#">neonatal guidelines</a>			
		Neonatal viral infections <sup>c</sup> can sometimes present with neonatal sepsis. Consider HSV testing and <b>ADD</b> IV aciclovir for suspected HSV infection; dose as per <a href="#">KEMH neonatal guidelines</a> . For further information refer to <a href="#">ASID perinatal guidelines</a>			
	Community acquired <u>neonatal</u> sepsis Meningitis excluded	IV gentamicin <b>AND</b> IV amoxicillin doses as per <a href="#">neonatal guidelines</a>	<b>ADD</b> vancomycin to standard protocol	Discuss with ID or Microbiology service	
		Neonatal viral infections <sup>c</sup> can sometimes present with neonatal sepsis. Consider HSV testing and <b>ADD</b> IV aciclovir for suspected HSV infection; dose as per <a href="#">KEMH neonatal guidelines</a> . For further information refer to <a href="#">ASID perinatal guidelines</a>			
	Community acquired <u>neonatal</u> sepsis Meningitis NOT excluded	IV cefotaxime <b>AND</b> IV amoxicillin <b>CONSIDER ADDING</b> IV gentamicin <b>IF</b> haemodynamically unstable doses as per <a href="#">neonatal guidelines</a>	<b>ADD</b> vancomycin to standard protocol	Discuss with ID or Microbiology service	
		Neonatal viral infections <sup>c</sup> can sometimes present with neonatal sepsis. Consider HSV testing and <b>ADD</b> IV aciclovir for suspected HSV infection; dose as per <a href="#">KEMH neonatal guidelines</a> . For further information refer to <a href="#">ASID perinatal guidelines</a>			

CLINICAL SCENARIO		DRUGS/DOSES			
		Standard Protocol	Known or Suspected MRSA <sup>a</sup>	Low risk Penicillin allergy <sup>b</sup>	High risk Penicillin allergy <sup>b</sup>
Sepsis	<p>Community acquired sepsis with hemodynamic instability, unknown source (<b>≥ 4 weeks</b>)</p> <p>Contact Infectious Diseases Physician if patient is admitted to ICU.</p>	<p><b>Give as soon as possible, ideally within 15 minutes of sepsis recognition</b></p> <p>IV <a href="#">ceftriaxone</a> 50mg/kg/dose (to a maximum of 2 grams) 12 hourly as a slow IV push over 5 minutes</p> <p><b>AND</b></p> <p>IV <a href="#">gentamicin</a><sup>d</sup> (refer to monograph for dose) Gentamicin may be given as a push over 3 to 5 minutes in critically unwell patients</p> <p><b>CONSIDER ADDING</b></p> <p>IV <a href="#">vancomycin</a><sup>e</sup> 15mg/kg/dose (to a maximum initial dose of 750mg) 6 hourly</p> <p><b>IF:</b></p> <ul style="list-style-type: none"> <li>• Gram-positive cocci are seen on Gram stain; <b>OR</b></li> <li>• has been recently treated with a penicillin, cephalosporin or carbapenem antibiotic <b>OR</b></li> <li>• patient is too unwell to undergo a lumbar puncture</li> </ul>	As per standard protocol		Discuss with ID or Microbiology service
		If HSV encephalitis suspected <b>ADD</b> IV <a href="#">aciclovir</a>			
Fever without focus	<p>Fever &gt;38°C without a source and with no hemodynamic instability (≥4 weeks to ≤3 months)</p> <p><b>OR</b></p> <p>Child ≥ 3 months old with suspicion of bacteraemia as determined by a senior clinician</p>	IV <a href="#">ceftriaxone</a> 50mg/kg/dose (to a maximum of 2 grams) 24 hourly	As per standard protocol		Discuss with ID or Microbiology service
		<p><a href="#">Febrile children &gt;3 months who are well without signs of serious illness</a> (as judged by a senior Clinician) are not routinely recommended antibiotics. Observation and investigation is recommended. If meningitis is suspected, refer to ChAMP empiric guidelines: <a href="#">Meningitis and meningoencephalitis</a></p>			

CLINICAL SCENARIO		DRUGS/DOSES			
		Standard Protocol	Known or Suspected MRSA <sup>a</sup>	Low risk Penicillin allergy <sup>b</sup>	High risk Penicillin allergy <sup>b</sup>
Sepsis	Healthcare-Associated Sepsis i.e. presumed serious bacterial infection with no known source (≥ 4 weeks): includes community acquired sepsis with central venous access device (CVAD) in place	Management of Healthcare-Associated Sepsis should take into consideration previous microbiological results. For therapeutic advice, discuss with Infectious Diseases or Clinical Microbiology services			
		<p><b>Give as soon as possible, ideally within 15 minutes of sepsis recognition</b></p> <p>IV <a href="#">cefepime</a> 50mg/kg/dose (to a maximum of 2 grams) 8 hourly</p> <p><b>AND</b></p> <p>IV <a href="#">vancomycin</a><sup>e</sup> 15mg/kg/dose (to a maximum initial dose of 750mg) 6 hourly</p> <p><b>CONSIDER ADDING (as a stat dose)</b></p> <p>IV <a href="#">gentamicin</a><sup>d</sup> (refer to monograph for dose)</p> <p>Gentamicin may be given as a push over 3 to 5 minutes in critically unwell patients</p>	As per standard protocol		Discuss with ID or Microbiology service
Asplenia	Fever in an asplenic patient	<p>IV <a href="#">ceftriaxone</a> 50mg/kg/dose (to a maximum of 2 grams) 24 hourly</p> <p><b>CONSIDER ADDING</b></p> <p>IV <a href="#">vancomycin</a><sup>e</sup> 15mg/kg/dose (to a maximum initial dose of 750mg) 6 hourly <b>IF</b> haemodynamically unstable</p>	Discuss with ID or Microbiology services	As per standard protocol	Discuss with ID or Microbiology services

CLINICAL SCENARIO		DRUGS/DOSES			
		Standard Protocol	Known or Suspected MRSA <sup>a</sup>	Low risk Penicillin allergy <sup>b</sup>	High risk Penicillin allergy <sup>b</sup>
Endovascular > 4 weeks old	Endocarditis or other endovascular infection; native valve or homograft	For patients with presumed endocarditis THREE sets of blood cultures should be taken from separate venepuncture sites prior to antibiotic administration.			
		IV <a href="#">benzylpenicillin</a> 50mg/kg/dose (to a maximum of 2.4 grams) 4 hourly <b>AND</b> IV <a href="#">flucloxacillin</a> 50mg/kg/dose (to a maximum of 2 grams) 4 hourly <b>AND</b> IV <a href="#">gentamicin</a> <sup>d</sup> (refer to monograph for dose)	<a href="#">gentamicin</a> <sup>d</sup> <b>AND</b> <a href="#">flucloxacillin</a> <sup>f</sup> <b>AND</b> <a href="#">vancomycin</a> <sup>e</sup>	<a href="#">gentamicin</a> <sup>d</sup> <b>AND</b> <a href="#">cefazolin</a> <sup>g</sup> <b>AND</b> <a href="#">vancomycin</a> <sup>e</sup>	<a href="#">gentamicin</a> <sup>d</sup> <b>AND</b> <a href="#">vancomycin</a> <sup>e</sup>
	Endocarditis or other endovascular infection; prosthetic valve or graft	For patients with presumed endocarditis THREE sets of blood cultures should be taken from separate venepuncture sites prior to antibiotic administration.			
		IV <a href="#">flucloxacillin</a> 50 mg/kg/dose (to a maximum of 2 grams) 4 hourly <b>AND</b> IV <a href="#">vancomycin</a> <sup>e</sup> 15mg/kg/dose (maximum initial dose 750mg) 6 hourly <b>AND</b> IV <a href="#">gentamicin</a> <sup>d</sup> (refer to monograph for dose)	As per standard protocol	<a href="#">gentamicin</a> <sup>d</sup> <b>AND</b> <a href="#">cefazolin</a> <sup>g</sup> <b>AND</b> <a href="#">vancomycin</a> <sup>e</sup>	<a href="#">gentamicin</a> <sup>d</sup> <b>AND</b> <a href="#">vancomycin</a> <sup>e</sup>

- a. Children known or suspected to be colonised with MRSA may need to have their therapy/prophylaxis modified. Children suspected of having MRSA include:
- Children previously colonised with MRSA
  - Household contacts of MRSA colonised individuals
  - In children who reside in regions with higher MRSA rates (e.g. Kimberley, Goldfields and the Pilbara) a lower threshold for suspected MRSA should be given
  - Children with recurrent skin infections or those unresponsive to  $\geq 48$  of beta-lactam therapy. For further advice, discuss with Microbiology or ID service
- b. Refer to the [ChAMP Beta-lactam Allergy Guideline](#)
- Low risk allergy: a delayed rash ( $>1$ hr after initial exposure) without mucosal or systemic involvement (without respiratory distress and/or cardiovascular compromise).
  - High risk allergy: an immediate rash ( $<1$ hr after exposure); anaphylaxis; severe cutaneous adverse reaction (e.g. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) and Stevens – Johnson syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)) or other severe systemic reaction.
- c. HSV infection may manifest as:
- Localised skin, eye and mucous membranes disease (~45%)
  - CNS disease (~30%)
  - Disseminated disease - liver, lungs +/- CNS (~25%)
- Maternal history of HSV may be absent in  $>75\%$  cases of neonatal HSV and up to 40% of neonatal HSV cases will not have skin lesions. Disseminated disease presents with viral sepsis, and may be indistinguishable from sepsis of another cause, i.e. respiratory collapse, pneumonitis, liver failure, DIC. CNS disease presents with lethargy, poor feeding, bulging fontanel and seizures.
- d. IV [gentamicin](#): may be given as a push over 3 to 5 minutes in critically unwell patients.
- Children  $\geq 4$  weeks – 10 years: 7.5mg/kg/dose (to a maximum of 320mg) 24 hourly
  - $>10$ years to 18 years: 6-7mg/kg/dose (to a maximum of 560mg) 24 hourly.
  - Therapeutic drug monitoring required if therapy extends beyond 72 hours.
- e. IV [vancomycin](#) **15mg/kg/dose** (maximum initial dose 750mg) 6 hourly via slow infusion. Therapeutic drug monitoring required.
- f. IV [flucloxacillin](#) **50mg/kg/dose** (to a maximum of 2 grams) 4 hourly.
- g. IV [cefazolin](#) **50mg/kg/dose** (to a maximum of 2 grams) 8 hourly (6 hourly dosing may be considered in discussion with ID).

### Related CAHS internal policies, procedures and guidelines

[Antimicrobial Stewardship Policy](#) (PCH Website)


[ChAMP Empiric Guidelines](#)

### References and related external legislation, policies, and guidelines

1. Antibiotic Writing Group (2021). eTG complete. West Melbourne, Therapeutic Guidelines Ltd.
2. Deep A (2020). BMJ Best Practice - Sepsis in Children, BMJ Publishing Group Limited.
3. Weiss S and Pomerantz W (2020). Septic shock in children: Rapid recognition and initial resuscitation (first hour), UptoDate.
4. Expert opinion – Paediatric Infectious Diseases Physicians



This document can be made available in alternative formats on request for a person with a disability.

File Path:	<a href="W:\Safety &amp; Quality\CAHS\CLOVERS MEDICAL Pharmacy\Procedures Protocols and Guidelines\ChAMP\Word\Empiric Guidelines\PCH Templated (ED Guidelines)"><u>W:\Safety &amp; Quality\CAHS\CLOVERS MEDICAL Pharmacy\Procedures Protocols and Guidelines\ChAMP\Word\Empiric Guidelines\PCH Templated (ED Guidelines)</u></a>		
Document Owner:	Head of Department – Infectious Diseases		
Reviewer / Team:	Children’s Antimicrobial Management Program Pharmacist		
Date First Issued:	November 2013	Last Reviewed:	November 2021
Amendment Dates:	April 2019, April 2020, October 2020, December 2020, November 2021	Next Review Date:	November 2024
Approved by:	Medication Safety Committee	Date:	December 2021
Endorsed by:	Chair, Drug and Therapeutics Committee	Date:	December 2021
Standards Applicable:	NSQHS Standards:  NSMHS: N/A Child Safe Standards: N/A		

Printed or personally saved electronic copies of this document are considered uncontrolled



Healthy kids, healthy communities

Compassion

Excellence

Collaboration

Accountability

Equity

Respect

Neonatology | Community Health | Mental Health | Perth Children’s Hospital